PDS BIOTECHNOLOGY CORPORATION PDSB 深 滬
等待開盤 08-19 09:30:00 美东时间
1.24
+0.050
+4.20%
華盛通- 最 高1.25
- 今 開1.22
- 成交量 31.68万股
- 最 低 1.1901
- 昨 收 1.19
- 總市值 5668.04万
- 52周最高 4.29
- 市盈率 靜 --
- 換手率 0.69%
- 52周最低 0.8505
- 委 比 -60.20%
- 總股本 4571.00万
- 歷史最高 17.85
- 量 比 0.84
- 振 幅 5.03%
- 歷史最低 0.615
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Piper Sandler Maintains Overweight on Precision Drilling, Raises Price Target to $74
Piper Sandler analyst Derek Podhaizer maintains Precision Drilling (NYSE:PDS) with a Overweight and raises the price target from $72 to $74.
08-14 23:07
PDS Biotechnology Q2 EPS $(0.21) Beats $(0.23) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 9.87 percent. This is a 8.7 percent increase over losses of $(0.23) per share from
08-13 19:00
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
PDS Biotech reported progress in its VERSATILE-003 Phase 3 clinical trial for PDS0101 in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma. Three abstracts on PDS0101 were presented at the 2025 ASCO annual meeting, highlighting positive data from the VERSATILE-002 trial. The company also announced the expansion of a colorectal cancer cohort in its Phase 2 trial following promising results. Financially, the company reported...
08-13 11:00
Insights into PDS Biotechnology's Upcoming Earnings
PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings re...
08-13 02:02
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
PDS Biotechnology Corporation, an immunotherapy company focused on treating cancers, has announced a conference call on August 13, 2025, at 8:00 AM ET to discuss its Q2 2025 financial results and provide updates on its clinical programs. The call will be accessible via telephone or webcast. PDS Biotech is advancing its lead program, PDS0101, in combination therapies for advanced HPV16-positive head and neck cancers.
08-06 12:00
RBC Capital Maintains Outperform on Precision Drilling, Raises Price Target to $100
RBC Capital analyst Keith Mackey maintains Precision Drilling (NYSE:PDS) with a Outperform and raises the price target from $89 to $100.
08-01 00:45
Precision Drilling Q2 EPS $0.77 and Sales $293.753M
Precision Drilling (NYSE:PDS) reported quarterly earnings of $0.77 per share. This is a 26.67 percent decrease over earnings of $1.05 per share from the same period last year. The company reported quarterly sales of
07-30 14:49
Earnings Scheduled For July 29, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is projected to repor...
07-29 16:32
Precision Drilling Q2 2025 Earnings Preview
Precision Drilling (NYSE:PDS) is scheduled to announce Q2 earnings results on Tuesday, July 29th, after market close. The consensus EPS Estimate is $0.04 and the consensus Revenue Estimate is $289.44M...
07-29 05:35
